Related Experiment Video
Updated: Mar 21, 2026
08:03
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
Published on: October 20, 2015
14.7K
Patient-Derived Prostate Cancer: from Basic Science to the Clinic
Gail P Risbridger1, Renea A Taylor2
1Monash Partners Comprehensive Cancer Consortium and Cancer Program, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Monash University, Wellington Road, Melbourne, VIC, 3800, Australia. gail.risbridger@monash.edu.
Hormones & Cancer
|May 15, 2016
Summary
Patient-derived xenografts (PDXs) are crucial for cancer research and drug development. This review examines challenges in establishing prostate cancer PDXs and highlights their value through clinical insights.
Area of Science:
- Oncology
- Translational Research
- Pre-clinical Drug Development
Background:
- Cancer modeling systems are vital for research discovery and therapeutic translation.
- Patient-derived specimens are a preferred model for pre-clinical drug development in many cancer types.
- Prostate cancer presents unique challenges in establishing patient-derived xenografts (PDXs) compared to other cancers like breast cancer.
Purpose of the Study:
- To review the challenges in developing prostate cancer patient-derived xenografts (PDXs).
- To highlight the importance and utility of existing prostate cancer PDXs and patient specimens.
- To demonstrate how limited PDX models have yielded significant clinical insights for prostate cancer.
Main Methods:
- Literature review on cancer modeling systems.
- Analysis of challenges specific to prostate cancer xenograft development.
- Case vignette analysis of insights gained from existing prostate cancer PDXs and patient specimens.
Main Results:
- Fewer prostate cancer PDXs exist compared to other cancer types, such as breast cancer.
- Despite limitations, existing prostate cancer PDXs and patient specimens have provided valuable clinical insights.
- Three case vignettes illustrate the successful application of PDX models in advancing prostate cancer understanding.
Conclusions:
- Overcoming challenges in prostate cancer PDX development is crucial for advancing pre-clinical research.
- Even limited numbers of prostate cancer PDXs can yield significant clinical benefits.
- Continued development and utilization of prostate cancer models are essential for improving patient outcomes.
